[144] BYLINE BANCORP, INC. SEC Filing
BYLINE BANCORP, INC. Form 144 notice reports a proposed sale of 1,999 common shares through Merrill Lynch on the NYSE, with an aggregate market value of $57,400 and 45,864,926 shares outstanding. The sale is scheduled for 09/12/2025. The shares to be sold match recently acquired stock awards: 444 shares granted 02/28/2022 and 1,555 shares granted 02/22/2025; both listed as compensation and acquired from the issuer. The filer reports no other sales in the past three months and affirms no undisclosed material adverse information.
- Full Rule 144 disclosure provided including broker, share count, acquisition dates, and sale date
- Shares originate from stock awards (02/28/2022 and 02/22/2025) and are identified as compensation, clarifying provenance
- Filer attests there is no undisclosed material adverse information and reports no other sales in past three months
- Insider selling of 1,999 shares may be viewed negatively by some investors despite small size
- Aggregate market value disclosed ($57,400) is small but provides limited insight into insider intent or broader ownership changes
Insights
TL;DR: Routine Rule 144 disclosure of insider sale equal to recent award vesting; immaterial relative to outstanding shares.
The filing documents a planned sale of 1,999 common shares valued at $57,400 on 09/12/2025 via Merrill Lynch. The shares correspond to two stock awards (02/28/2022 and 02/22/2025) paid as compensation, indicating this is likely routine disposition of vested awards rather than a market-moving divestiture. With 45.86 million shares outstanding, the sale size is de minimis on a shares-outstanding basis. The disclosure satisfies Rule 144 notice requirements and includes the filer’s attestation about material information.
TL;DR: Compliance-focused filing showing transparent insider selling tied to compensation awards, standard governance practice.
The Form 144 provides required information: broker, share count, acquisition dates, nature of acquisition, and planned sale date. Listing the awards and that payment was compensation helps clarify the provenance of the shares, reducing governance concerns about undisclosed transfers. Absence of other recent sales and the filer’s attestation about material adverse information further support that this is a routine, documented transaction under Rule 144 and not an indication of undisclosed corporate issues.